4 months ago
1
The Bombay High Court has permanently restrained Anrose Pharma from utilizing the trademark ‘ZEROVOL-P’ for symptom alleviation medicines, holding it “virtually identical” to IPCA Laboratories’ registered trademark ‘ZERODOL’. The tribunal directed the suspect to wage ₹15 lakh arsenic costs wrong 8 weeks, failing which involvement astatine 8% per annum volition apply.
Justice Arif S. Doctor, deciding IPCA Laboratories Limited vs Anrose Pharma, recovered the defendant’s adoption of the impugned people “plainly dishonest and without immoderate owed cause” and warned of a superior hazard of deception successful the pharmaceutical trade.
“A perusal of the rival trademarks makes plain that they are virtually identical. The Defendant has not truthful overmuch arsenic even attempted to marque retired a lawsuit of honorable oregon bona fide adoption of the people ZEROVOL–P,” the court observed, noting that the suspect did not look contempt work of summons and the plaintiff’s grounds stood uncontroverted.
IPCA, registered proprietor of ‘ZERODOL’, told the court it has utilized the people since 2003 for symptom absorption medicines, supported by invoices, sales turnover and promotional evidence. The institution markets combinations including ZERODOL–P, ZERODOL–PT, ZERODOL–S, ZERODOL–MR and ZERODOL–TH.
Recording the plaintiff’s goodwill and distinctiveness, the court said, “The evidence establishes that ZERODOL has acquired distinctiveness and is exclusively associated by the nationalist and persons successful the commercialized with the Plaintiff alone. Thus, the Plaintiff has established goodwill successful its registered trademark ZERODOL.”
On the stricter trial applicable to medicinal products, the court held, “Given that the impugned people is virtually identical to the Plaintiff’s registered trademark and some are utilized successful respect of medicinal oregon pharmaceutical products, the likelihood of disorder is imminent. Thus, the usage by the Defendant of the impugned trade mark would almost certainly result successful the goods of the Defendant being passed disconnected arsenic those of the Plaintiff.”
While IPCA sought ₹5,00,000 successful punitive damages with 21% interest, the tribunal declined damages for privation of proof, “The Plaintiff has not led immoderate grounds successful enactment of the Plaintiffs assertion for damages oregon nonaccomplishment suffered.”
Justice Doctor said the suit was governed by the Commercial Courts Act, which mandates that costs ordinarily travel the lawsuit and beryllium awarded to the palmy party. He noted the defendant’s nonaccomplishment to look oregon cross-examine and described the adoption of the people arsenic “dishonest and actuated successful atrocious faith.” The justice added that, “the impugned products being aesculapian products, a stricter bid of costs indispensable follow, arsenic the Plaintiffs person profited astatine the imaginable hazard to the nationalist astatine large.”
Accordingly, the suit was decreed successful presumption of supplication clauses (a), (b) and (d)—restraining the usage of ‘ZEROVOL–P’/‘ZEROVOL’ oregon immoderate people deceptively similar to ‘ZERODOL’ and directing delivery up of each infringing materials for destruction. The operative bid states:
“The Defendant shall pay costs of ₹15,00,000/- to the Plaintiff wrong a play of 8 weeks from today. In the event, the costs are not paid wrong a play of 8 weeks from today, involvement astatine the complaint of 8% shall apply.”
